Epoxides

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Retrieved on: 
Thursday, July 29, 2021
Chemical compounds, Health care, Health sciences, Muscarinic antagonists, Boehringer Ingelheim, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Abbreviated New Drug Application, Inhaler

PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.

Key Points: 
  • PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
  • U.S. sales of Spiriva Handihaler were $1.5 billion for the 12 months ending May, 2021 according to IQVIA, although actual generic market values are expected to be lower.
  • "With generic Spiriva Handihaler, our strategic relationship with Respirent now includes three inhaler products, each of which has the potential to be a meaningful contributor to our company's financial performance.
  • The generic Spiriva Handihaler product is currently in development and tracking to Abbreviated New Drug Application (ANDA) submission in 2023."

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Friday, July 9, 2021
Pharmaceutical, Health, Other Health, Drugs, Orphan drugs, Clinical medicine, Chemical compounds, Carfilzomib, Epoxides, Morpholines, Peptides, Multiple myeloma, Proteasome inhibitor, Breakthrough therapy, Daratumumab, Multiple Myeloma, KYPROLIS® (carfilzomib) for injection, BeiGene, MULTIPLE MYELOMA, KYPROLIS® (CARFILZOMIB) FOR INJECTION, BEIGENE

The approval of KYPROLIS provides us with an important opportunity to offer adult patients in China with relapsed or refractory multiple myeloma a proteasome inhibitor with high selectivity and irreversibility as a treatment option for their disease.

Key Points: 
  • The approval of KYPROLIS provides us with an important opportunity to offer adult patients in China with relapsed or refractory multiple myeloma a proteasome inhibitor with high selectivity and irreversibility as a treatment option for their disease.
  • KYPROLIS is approved in the U.S. for the following:
    as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • KYPROLIS is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS monotherapy.

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

Retrieved on: 
Tuesday, July 6, 2021
Health sciences, Chemical compounds, Chemistry, Alcohols, Cyclopropanes, Epoxides, Ketones, Tigilanol tiglate, Pharmaceutical industry, Cancer

This approval represents Australia's first pharmaceutical treatment available for all grades of canine non-metastatic MCT.

Key Points: 
  • This approval represents Australia's first pharmaceutical treatment available for all grades of canine non-metastatic MCT.
  • QBiotics' CEO and Managing Director, Dr Victoria Gordon said "APVMA approval of STELFONTAmarks an important milestone for QBiotics.
  • As an Australian company with a strong heritage in discovery, research and development, we are proud that our lead molecule will now be available to treat cancer in Australian dogs."
  • In this study,a single injection of STELFONTA induced a 75% Complete Response (where the tumour is completely destroyed), compared to untreated control dogs (p=0.001).

Hangzhou Chance Pharmaceuticals Announces NMPA Acceptance of Marketing Authorization Application for CXF11

Retrieved on: 
Friday, July 2, 2021
Respiratory diseases, Chemical compounds, Pulmonology, Chronic lower respiratory diseases, Muscarinic antagonists, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Bronchospasm

HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).
  • The NMPA Acceptance of Marketing Authorization Application for CXF11is the first important milestone in product development for Chance.
  • CXF11 is Chances tiotropium bromide inhalation drug intended for prevention of bronchospasm in adults with chronic obstructive pulmonary disease (COPD).
  • Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the worlds most debilitating diseases.

Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder (generic for Kyprolis®)

Retrieved on: 
Wednesday, June 16, 2021
Carfilzomib, Epoxides, Morpholines, Peptides, Natco, Onyx, Breckenridge

BERLIN, Conn., June 16, 2021 /PRNewswire/ --Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Carfilzomib Intravenous Powder (generic for Kyprolis).

Key Points: 
  • BERLIN, Conn., June 16, 2021 /PRNewswire/ --Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Carfilzomib Intravenous Powder (generic for Kyprolis).
  • Breckenridge received final approval for the 10mg and 60mg strengths and tentative approval for the 30mg strength.
  • Onyx Therapeutics, Inc., Breckenridge and Natco have reached a Settlement Agreement and the District Court case against Breckenridge and Natco has been dismissed.
  • According to industry sales data, Kyprolisgenerated annual sales of $711 million during the twelve months ending April 2021.

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Chemical compounds, Clinical medicine, Antibiotics, Epoxides, Phosphonic acids, Fosfomycin, Urinary tract infection, Pleuromutilin, Pyelonephritis, Forward-looking statement, Lefamulin

Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Key Points: 
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics\xe2\x80\x99 views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics\xe2\x80\x99 views as of any date subsequent to the date of this press release.\n'

Picarro Adds Ethylene Oxide, Hydrogen Peroxide, and Methane Analyzers to GSA Schedule

Retrieved on: 
Tuesday, April 20, 2021
Biocides, Chemistry, Physical sciences, Natural sciences, Spectroscopy, Epoxides, Ethylene oxide, Fungicides, Cavity ring-down spectroscopy, Sterilization

As a result, U.S. government agencies and prime contractors can now assemble a complete system from a selection of 62 analyzers, peripherals, and kits through the GSA contract.\nThree analyzers in high demand are among the recent additions.

Key Points: 
  • As a result, U.S. government agencies and prime contractors can now assemble a complete system from a selection of 62 analyzers, peripherals, and kits through the GSA contract.\nThree analyzers in high demand are among the recent additions.
  • The G2910 Ethylene Oxide (EtO) Analyzer , a critical tool for monitoring stack, indoor air, and fugitive emissions, enables organizations to better manage the environmental impact of this gas that is used in medical sterilization.
  • Picarro\'s gas analyzers provide researchers, policy makers, regulators and businesses with access to technology that expands and improves their understanding of air quality.
  • Our patented Cavity Ring-Down Spectroscopy (CRDS) is at the heart of all Picarro instruments, enabling the detection of target molecules at parts per billion or better resolution.

Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 1, 2021
Medical specialties, Antibiotics, Epoxides, Fosfomycin, Urinary tract infection, Infection, Clinical medicine, Health sciences

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 2:15p.m.

Key Points: 
  • DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 2:15p.m.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin), the first pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTIs), including acute pyelonephritis.

Global Epoxidized Soybean Oil Market Trends, Forecast and Competitive Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Food, Beverage, Retail, Domesticated plants, Crops, Agronomy, Epoxides, Chinese cuisine, Fodder, Japanese cuisine, Soybean, Epoxidized soybean oil

The study includes the epoxidized soybean oil market size and forecast for the global epoxidized soybean oil market through 2024, segmented by raw material, application, and region.

Key Points: 
  • The study includes the epoxidized soybean oil market size and forecast for the global epoxidized soybean oil market through 2024, segmented by raw material, application, and region.
  • Some of the features of Global Epoxidized Soybean Oil Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:
    Market size estimates: Global epoxidized soybean oil market size estimation in terms of value ($M) shipment.
  • Segmentation analysis: Global market size by raw material, application, and region
    Regional analysis: Global epoxidized soybean oil market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
    Growth opportunities: Analysis on growth opportunities in different applications and regions for epoxidized soybean oil in the global epoxidized soybean oil market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, epoxidized soybean oil in the global epoxidized soybean oil market.

Mycotoxin Testing Market is set to experience a high value growth of more than 7% CAGR over the next ten years - Persistence Market Research

Retrieved on: 
Friday, March 19, 2021
Epoxides, Enones, Fusarium, Mycotoxins, Nivalenol, Compound annual growth rate, Organic compounds, Chemical substances, Chemistry

As such, the global mycotoxin testing market is set to experience a high value growth of more than 7% CAGR over the next ten years.

Key Points: 
  • As such, the global mycotoxin testing market is set to experience a high value growth of more than 7% CAGR over the next ten years.
  • By type, deoxynivalenol is among the most tested mycotoxin, with the largest market value share of around 28% in 2020.
  • The mycotoxin testing market in East Asia is projected to expand at an impressive CAGR of close to 9% through 2030.
  • Players operating in the mycotoxin testing market are focusing on expanding their businesses globally through strategic acquisitions and mergers.